JP2018500274A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500274A5
JP2018500274A5 JP2017516948A JP2017516948A JP2018500274A5 JP 2018500274 A5 JP2018500274 A5 JP 2018500274A5 JP 2017516948 A JP2017516948 A JP 2017516948A JP 2017516948 A JP2017516948 A JP 2017516948A JP 2018500274 A5 JP2018500274 A5 JP 2018500274A5
Authority
JP
Japan
Prior art keywords
group
core sequence
seq
ala
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516948A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851965B2 (ja
JP2018500274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/052467 external-priority patent/WO2016049580A2/en
Publication of JP2018500274A publication Critical patent/JP2018500274A/ja
Publication of JP2018500274A5 publication Critical patent/JP2018500274A5/ja
Application granted granted Critical
Publication of JP6851965B2 publication Critical patent/JP6851965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516948A 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Active JP6851965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036502A Division JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2018500274A JP2018500274A (ja) 2018-01-11
JP2018500274A5 true JP2018500274A5 (enExample) 2019-05-09
JP6851965B2 JP6851965B2 (ja) 2021-03-31

Family

ID=55582262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Country Status (7)

Country Link
US (5) US10030048B2 (enExample)
EP (1) EP3197474B1 (enExample)
JP (3) JP6851965B2 (enExample)
CN (2) CN106999535B (enExample)
AU (2) AU2015320341B2 (enExample)
CA (1) CA2999711A1 (enExample)
WO (1) WO2016049580A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
US20220133837A1 (en) * 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
EP0487617B1 (en) 1989-08-14 1996-10-02 The Regents Of The University Of California Synthetic peptides that enhance cell binding
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
JP4943848B2 (ja) * 2003-10-07 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｎｉｋに対する抗体、その調製および使用
US20060211075A1 (en) * 2005-03-02 2006-09-21 The Albert Einstein College Of Medicine Of Yeshiva University Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
US8614186B2 (en) * 2009-05-27 2013-12-24 Dana-Farber Cancer Institute, Inc. Inhibition of inflammation using antagonists of MUC1
CA2785038A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
US20220133837A1 (en) 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Similar Documents

Publication Publication Date Title
ES2581381T3 (es) Composiciones y métodos de inhibición de la gripe
ES2212121T3 (es) Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12).
AU2019260757A1 (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
US20120316103A1 (en) Cyclic antimicrobial peptides
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
ES3058033T3 (en) Long-acting adrenomedullin derivatives
JP2022546130A (ja) 合成抗菌ペプチド
JP2018527288A5 (enExample)
JPWO2019156137A5 (enExample)
MY199821A (en) Modified lipidated relaxin b chain peptides and their therapeutic use
US20160168203A1 (en) Cyclic Antimicrobial Peptides
DK2956155T3 (en) Short bioactive peptides to promote wound healing
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
CA2045578A1 (en) Anaphylatoxin-receptor ligands
JP2016521746A5 (enExample)
HRP20171048T1 (hr) Novi agonisti angiotenzinskog receptora tipa 2 (at2) i njihove upotrebe
JP2016513107A5 (enExample)
JP2021091728A5 (enExample)
JP2023010979A5 (enExample)
PT99940A (pt) Processo de preparacao de ligandos hexa- e heptapeptidicos do receptor da anafilatoxina e de composicoes farmaceuticas
JP6548126B2 (ja) Ｉｉｉ型コラーゲン産生促進剤
KR20170052613A (ko) 효모/곰팡이에 의해 유발되는 감염을 치료하기 위한 시스테아민의 사용
JPWO2021070696A5 (enExample)
ES2476590T3 (es) P�ptidos antimicrobianos mejorados
JP2008534485A (ja) スタテリンペプチドおよび薬剤における使用